Objective: This study compared the usefulness of self-collected (SC) and clinician-collected (CC) materials for cervical cytology and human papillomavirus (HPV) genotyping. Study Design: Fifty women with previous positive cytology and who were undergoing regular checkups were included in the study. CC samples were collected using a Cervex-Brush Combi with liquid-based cytology. One month later, SC material was acquired using the Rovers Viba-brush vaginal sampler, and fixed at home. Thin-layer specimens were prepared from both samples and HPV status was analyzed using a linear array. Results: A total of 37/50 CC (74%) and 41/50 SC (82%) cases were positive for HPV. Pap tests identified high-grade squamous intraepithelial lesions in 11 (22%) and seven (14%) patients, low-grade squamous intraepithelial lesions in 19 (38%) and 16 (32%), atypical squamous cells of undetermined significance in 2 (4%) and 0 patients, and NILM (negative for intraepithelial lesion or malignancy) in 18 (36%) and 27 (54%) patients in the CC and SC groups, respectively. Conclusions: SC material had a lower positive cytology rate, but a higher HPV-positive rate than CC material. These results suggest that a combination of Pap and HPV tests on SC material may provide a diagnostic strategy with high sensitivity and specificity.

1.
Curado MP, Edwards B, Shin HR, Ferlay J, Heanue M, Boyle P, Storm H: Cancer incidence in five continents. IARC scientific publications No.160. Lyon, IARC, 2007.
2.
WHO: Cervical cancer screening in developing countries: report of a WHO consultation. Geneva, World Health Organization, 2001.
3.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
4.
Franco EL, Harper DM: Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005;23:2388–2394.
5.
Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, Anh PTH, Ferreccio C, Hieu NT, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, M-Meijer CJL, Franceschi S, IARC HPV prevalence Surveys Study Group: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991–998.
6.
Dutra I, Santos MR, Soares M, Couto AR, Bruges-Armas M, Teixeira F, Monjardino L, Hodgson S, Bruges-Armas J: Characterisation of human papillomavirus (HPV) genotypes in the Azorean population, Terceira island. Infect Agent Cancer 2008;3:1–5.
7.
Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63–73.
8.
Jacob MV, Walboomers JM, Snijders PJF, Voorhorst FJ, Verheijen RHM, Fransen-Daalmeijer N, Meijer CJLM: Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221–227.
9.
Inoue M, Sakaguchi J, Sasagawa T, Tango M: The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 2006;16:1007–1013.
10.
Sasagawa T, Dong Y, Saijoh K, Satake S, Tateno M, Inoue M: Human papillomavirus infection and risk determinants for squamous intraepithelial lesion and cervical cancer in Japan. Jpn J Cancer Res 1997;88:376–384.
11.
Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker E: A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3:14.
12.
Schiffman M, Herrero R, Hidesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT: HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87–93.
13.
Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796–1807.
14.
de Villers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004;324:518–527.
15.
Peto J, Gilham C, Deacon J Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M: Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2003;91:942–953.
16.
Franceschi S, Cliffford GM: Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005;97:938–939.
17.
Bais AG, van Kemenade FJ, Berkhof J, Verheijen RHM, Snijider PJF, Voohorst F, Babovic M, van Ballegooijen M, Helmerhorst TJM, Meijer CJLM: Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007;120:1505–1510.
18.
Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A: HPV DNA testing self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81–86.
19.
Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, van Kemenade F, Fransen Daalmeijer N, Hesselink AT, Berkhof J, Snijders PJ: High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006;44:2518–2523.
20.
Sasieni PD, Cuzick J, Lynch-Farmery E: Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996;73:1001–1005.
21.
Franco EL: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003;31:89–96.
22.
Dzuba IG, Díaz EY, Allen B, Leonard YF, Ponce ECL, Shan KV, Bishai D, Lorincz A, Ferris D, Turnbull B, Avila HM, Salmerón J: The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Wom Health 2002;11:265–275.
23.
Gravitt PE, Lancy JV Jr, Brinton LA, Barnes WA, Kornegay JR, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Zaino R, Hildesheim A: Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase cain reaction. Cancer Epidemiol Biomark Prev 2001;10:95–100.
24.
Moscicki AB: Comparison between methods for human papillomavirus DNA testing: a model for self-testing in young women. J Infect Dis 1993;167:723–725.
25.
Harper DM, Hildesheim A, Cobb JL, Greenberg M, Vaught J, Lrincz AT: Collection devices for human papillomavirus. J Fam Pract 1999;48:531–535.
26.
Coutlée F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vézina S, Coté P, Macleod J, Voyer H, Forest P, Walmsley S, The Canadian Women’s HIV Study Group, Franco E: Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J Clin Microbiol 2006;44:1998–2006.
27.
Dunn ST, Allen RA, Wang S, Walker J, Schiffman M: DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. J Virol Methods 2007;143:45–54.
28.
Steinau M, Swan DC, Unger ER: Type-specific reproducibility of the Roche linear array HPV genotyping test. J Clin Virol 2008;42:412–414.
29.
Woo YL, Damay I, Stanley M, Crawford R, Sterling J: The use of HPV linear array assay for multiple HPV typing on archival frozen tissue and DNA specimens. J Virol Mrthods 2007;142:226–230.
30.
Schiffman M, Castle PE: The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101–2104.
31.
Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL: Chapter 3:HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(suppl 3):S3/26–S3/34.
32.
Konno R, Shin HR, Kim YT, Song YS, Sasagawa T, Inoue M, Park JS: Human papillomavirus infection and cervical cancer prevention in japan and korea. Vaccine 2008;26(suppl):M30–M42.
33.
Bao YP, Smith JS, Qiao YL; ACCPAB members: Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008;18:71–79.
34.
Bhatla N, Lal N, Bao YP, Ng T, Qiao YL: A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine 2008;26:2811–2817.
35.
Stevens MP, Rudland E, Garland SM, Tabrizi SN: Assessment of MagNA Pure LC Extraction System for detection of human papillomavirus (HPV) DNA in PresevCyt samples by the Roche amplicor and linear array HPV tests. J Clin Microbiol 2010;44:2428–2433.
36.
Harper DM, Noll WW, Belloni DR, Ole BF: Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed-biplogic concordance and women’s preferences. Am J Obstet Gynecol 2002;186:365–373.
37.
Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Jaspars LH, Voorhorst FJ, Verheijen RH, Meijer CJ: Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 2002;55:435–439.
38.
Hillemans P, Kimmig R, Huttemann U, Dannecker C, Thalaer CJ: Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet 1999;354:1970.
39.
Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F: Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007:105; 530–535.
40.
Ogilvie GS Partrick DM, Schulzer M, Sellors JW, Petric M, Chambers K, White R, FitzGerald JM: Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sen Transm Infect 2005;81:207–212.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.